Companies to Develop Cancer Therapeutic Targets
Metamark, Janssen Biotech Ink Potential $365M Deal
By Marie Powers
Tuesday, December 20, 2011
Privately held Metamark Genetics Inc. landed a big fish, inking a research, collaboration and license agreement with Johnson & Johnson subsidiary Janssen Biotech Inc. potentially worth $365 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.